4.6 Article

The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders

期刊

TRANSPLANTATION
卷 94, 期 8, 页码 784-793

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0b013e318269e64f

关键词

Epstein-Barr virus infection; Immunosuppression; Lymphoproliferative disorder; Transplantation

资金

  1. Genzyme
  2. CSL Behring
  3. Mundipharma
  4. Amgen
  5. Roche
  6. BMS
  7. Pfizer
  8. Astellas
  9. Novartis
  10. Fresenius
  11. Medical Research Council [G9818340B] Funding Source: researchfish

向作者/读者索取更多资源

Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据